Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort-Reference-Cited by-同舟云学术

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Published:2019-07 Issue:1 Volume:81 Page:143-151
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Faiz Sarah,Giovannelli Jonathan,Podevin Céline,Jachiet Marie,Bouaziz Jean-David,Reguiai Ziad,Nosbaum Audrey,Lasek Audrey,Ferrier le Bouedec Marie-Christine,Du Thanh Aurélie,Raison-Peyron Nadia,Tetart Florence,Duval-Modeste Anne-Bénédicte,Misery Laurent,Aubin François,Dompmartin Anne,Morice Cécile,Droitcourt Catherine,Soria Angèle,Arnault Jean-Philippe,Delaunay Juliette,Mahé Emmanuel,Richard Marie-Aleth,Schoeffler Amélie,Lacour Jean-Philippe,Begon Edouard,Walter-Lepage Amélie,Dillies Anne-Sophie,Rappelle-Duruy Sandrine,Barete Stéphane,Bellon Nathalia,Bénéton Nathalie,Valois Aude,Barbarot Sébastien,Sénéchal Julien,Staumont-Sallé Delphine

Funder

Regenron

Publisher

Elsevier BV

Subject

Dermatology

Reference15 articles.

1. Epidemiology of atopic dermatitis in adults: results from an international survey;Barbarot;Allergy,2018

2. Two Phase 3 trials of dupilumab versus placebo in AD;Simpson;N Engl J Med,2016

3. Long-term management of moderate-to-severe AD with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017

4. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

5. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”;Hanifin;J Am Acad Dermatol,2004

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Moderate-to-Severe Atopic Dermatitis in Adults: A Cross-Sectional Survey of Dermatologists Within the Asia–Pacific Region;Dermatology and Therapy;2024-08-20

2. Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis;Clinical and Translational Allergy;2024-08

3. Prolonged hypereosinophilia associated with dupilumab for atopic dermatitis: A case series and review of literature;JAAD Case Reports;2024-08

4. Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity;Journal of the European Academy of Dermatology and Venereology;2024-07-31

5. Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?;Journal of Personalized Medicine;2024-07-22